Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$2.20 CAD
Change Today +0.10 / 4.76%
Volume 23.0K
As of 3:58 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

helix biopharma corp (HBP) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/15/15 - C$2.35
52 Week Low
02/6/15 - C$1.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HELIX BIOPHARMA CORP (HBP)

Related News

No related news articles were found.

helix biopharma corp (HBP) Related Businessweek News

No Related Businessweek News Found

helix biopharma corp (HBP) Details

Helix BioPharma Corp., a biopharmaceutical company, develops drugs for the prevention and treatment of cancer based on its proprietary technologies. The company focuses on the development of L-DOS47 that is in phase I/II clinical trial for the treatment of inoperable, locally advanced, and recurrent or metastatic non-small cell lung cancer; and Topical Interferon Alpha-2b, which has completed phase II study for the treatment of low-grade cervical lesions and ano-genital warts caused by human papilloma virus infections. It also offers DOS47, a patented oncology platform technology that derives a therapeutic pharmacological effect by acting upon a naturally occurring substance in the body. Helix BioPharma Corp. is headquartered in Aurora, Canada.

11.5 Employees
Last Reported Date: 10/23/14

helix biopharma corp (HBP) Top Compensated Officers

Chief Executive Officer, President, Non-Indep...
Total Annual Compensation: C$325.0K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$260.0K
Chief Scientific Officer
Total Annual Compensation: C$275.0K
Compensation as of Fiscal Year 2014.

helix biopharma corp (HBP) Key Developments

Helix Biopharma Corp. Appoints Gary Littlejohn as Director

Helix BioPharma Corp. announced that Mr. Gary Littlejohn has been appointed as a director of Helix, effective as of September 23, 2015. To help facilitate a smooth leadership transition while Helix searches for a new permanent President and Chief Executive Officer, he has been appointed as a Consultant to Helix effective as of September 29, 2015. As previously disclosed, Mr. Robert Verhagen will continue to act as Helix's President and Chief Executive Officer until November 1, 2015. Mr. Littlejohn brings over 30 years of experience in the financial and biopharmaceutical industries.

Helix BioPharma Corp. Announces Resignation of Stacy L. Wills from the Board of Directors, Effective September 25, 2015

Helix BioPharma Corp. announced that Stacy L. Wills has voluntarily resigned from Helix's board of directors, effective as of September 25, 2015.

Helix Biopharma Corp. Announces Executive Changes, Effective November 1, 2015

Helix BioPharma Corp. announced that Robert Verhagen has resigned as President and Chief Executive Officer (CEO), effective as of November 1, 2015, and as a member of the Board of Directors, effective immediately. Mr. Verhagen will continue to serve as CEO to assist in the company's management transition and he has been with Helix since 2012. In the event that the Board has not appointed a new Chief Executive Officer by November 1, 2015, Helix's Board of Directors intends to appoint Yvon Bastien, Chairman of the Board, to assume the role of President and Chief Executive Officer on an interim basis. Mr. Bastien joined Helix's Board of Directors in 2013 and has over 30 years of experience in the life sciences industry. His previous leadership roles include CEO and President at Sanofi Canada, Founder and President at Delta Healthcare, and President at Jouveinal. He had also served in various senior roles a CIBA Geigy in Switzerland, Laboratorie Debat in France and IMS Canada. Mr. Bastien is currently the Chair of the Compensation Committee of Telesta Therapeutics and a board member of HLS Therapeutics. His previous board affiliations include Trillium Health Care, Saint Bernard Soap Company, PainCeptor Pharmaceuticals, Enobia Pharmaceuticals and Vitamin Angels.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HBP:CN C$2.20 CAD +0.10

HBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HBP.
View Industry Companies

Industry Analysis


Industry Average

Valuation HBP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 18.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HELIX BIOPHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at